Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion

European Heart Journal

Volumn 34, Issue 8, 2013, Pages 615-624

  Zheng, Chunyu ^a   Azcutia, Veronica ^a   Aikawa, Elena ^a   Figueiredo, Jose Luiz ^a   Croce, Kevin ^a   Sonoki, Hiroyuki ^a,b   Sacks, Frank M ^c   Luscinskas, Francis W ^a   Aikawa, Masanori ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b KOWA COMPANY LTD   (Japan)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Apolipoprotein CIII; Atherosclerosis; HMG CoA reductase inhibitors; Monocytes; Vascular endothelial cells

Indexed keywords

APOLIPOPROTEIN C3; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PITAVASTATIN; PRAVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL LINE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFICACY; DRUG INHIBITION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LOSS OF FUNCTION MUTATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PURIFICATION; SAPHENOUS VEIN; SHEAR STRESS; VASCULAR ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA; APOLIPOPROTEIN C-III; CELL ADHESION; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; NF-KAPPA B; QUINOLINES; SAPHENOUS VEIN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84874474015     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs271     Document Type: Article

References (35)

1. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009;27:165-197.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
3. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, Fukumoto Y, Schoen FJ, Witztum JL, Libby P. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002;106:1390-1396.
4. Cybulsky MI, Lichtman AH, Hajra L, Iiyama K. Leukocyte adhesion molecules in atherogenesis. Clin Chim Acta 1999;286:207-218.
5. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 2004;13:125-138.
6. Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 2011;124:2065-2072.
7. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102:1886-1892.
8. Scheffer PG, Teerlink T, Dekker JM, Bos G, Nijpels G, Diamant M, Kostense PJ, Stehouwer CD, Heine RJ. Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study. Clin Chem 2008; 54:1325-1330.
9. Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, Serajuddin H, Francone OL, Breslow JL, Tall AR. A mouse model with features of familial combined hyperlip-idemia. Science 1997;275:391-394.
10. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994;269:23610-23616.
11. Juntti-Berggren L, Refai E, Appelskog I, Andersson M, Imreh G, Dekki N, Uhles S, Yu L, Griffiths WJ, Zaitsev S, Leibiger I, Yang SN, Olivecrona G, Jornvall H, Berggren PO. Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. Proc Natl Acad Sci USA 2004;101:10090-10094.
12. Sol EM, Sundsten T, Bergsten P. Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells. Lipids Health Dis 2009;8:3.
13. Holmberg R, Refai E, Hoog A, Crooke RM, Graham M, Olivecrona G, Berggren PO, Juntti-Berggren L. Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci USA 2011;108:10685-10689.
14. Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010;121:1722-1734.
15. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006;114:681-687.
16. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipopro-tein CIII in apolipoprotein B lipoproteins enhances the adhesion of human mono-cytic cells to endothelial cells. Circulation 2006;113:691-700.
17. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002;8:1257-1262.
18. Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol 2012; 73:518-535.
19. Cicha I, Beronov K, Ramirez EL, Osterode K, Goppelt-Struebe M, Raaz D, Yilmaz A, Daniel WG, Garlichs CD. Shear stress preconditioning modulates endothelial susceptibility to circulating TNF-alpha and monocytic cell recruitment in a simplified model of arterial bifurcations. Atherosclerosis 2009;207:93-102.
20. Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, Kim JH, Kim W, Jeong MH, Cho JG, Park JC, Kang JC. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and nuclear factor-kappaB in endothelial cells. J Cardiovasc Pharmacol 2007;49:376-383.
21. Bernot D, Benoliel AM, Peiretti F, Lopez S, Bonardo B, Bongrand P, Juhan-Vague I, Nalbone G. Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor alpha. J Cardiovasc Pharmacol 2003; 41:316-324.
22. Dunoyer-Geindre S, Dimitrova Y, Fish RJ, Satta N, Reber G, Kruithof EK, de Moerloose P. Fluvastatin increases the expression of adhesion molecules, mono-cyte chemoattractant protein-1 and tissue factor in HUVEC stimulated by patient IgG fractions containing antiphospholipid antibodies. Thromb Haemost 2005; 93:339-345.
23. Eccles KA, Sowden H, Porter KE, Parkin SM, Homer-Vanniasinkam S, Graham AM. Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 2008;200:69-79.
24. Sacks FM, Alaupovic P, Moye LA. Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins. Am J Cardiol 2002;90:165-167.
25. Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fievet C, Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett 1999;452:160-164.
26. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107:1423-1432.
27. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome prolifera-tors as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995;270:13470-13475.
28. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855-1862.
29. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-283.
30. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001;103:993-999.
31. Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 2007; 101:234-247.
32. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999;107:85-97.
33. Hanyu M, Kume N, Ikeda T, Minami M, Kita T, Komeda M. VCAM-1 expression precedes macrophage infiltration into subendothelium of vein grafts interposed into carotid arteries in hypercholesterolemic rabbits-a potential role in vein graft atherosclerosis. Atherosclerosis 2001;158:313-319.
34. Storling J, Juntti-Berggren L, Olivecrona G, Prause MC, Berggren PO, Mandrup-Poulsen T. Apolipoprotein CIII reduces proinflammatory cytokine-induced apoptosis in rat pancreatic islets via the Akt prosurvival pathway. Endocrinology 2011;152:3040-3048.
35. Lin R, Liu J, Peng N, Yang G, Gan W, Wang W. Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull 2005;28:1630-1634.